Use of Thrombopoietic Agents for the Thrombocytopenia of Liver Disease

Seminars in Hematology

Volumn 47, Issue 3, 2010, Pages 266-273

  Tillmann, Hans L ^a   McHutchison, John G ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AKR 501; E 5501; ELTROMBOPAG; IMMUNOGLOBULIN D ANTIBODY; INTERFERON; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PLACEBO; RECOMBINANT INTERLEUKIN 11; RIBAVIRIN; ROMIPLOSTIM; THROMBOPOIETIN; THROMBOPOIETIN MIMETIC AGENT; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ARTICLE; BLEEDING; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG USE; HEMOSTASIS; HEPATITIS C; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; LIVER CIRRHOSIS; LIVER DISEASE; NAUSEA; NONHUMAN; PATHOPHYSIOLOGY; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLENECTOMY; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOSIS; XEROSTOMIA;

HUMANS; LIVER DISEASES; THROMBOCYTOPENIA; THROMBOPOIETIN;

EID: 77953879139     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2010.04.003     Document Type: Article

References (67)

1. Gressner O.A., Weiskirchen R., Gressner A.M. Biomarkers of liver fibrosis: clinical translation of molecular pathogenesis or based on liver-dependent malfunction tests. Clin Chim Acta 2007, 381:107-113.
2. Bashour F.N., Teran J.C., Mullen K.D. Prevalence of peripheral blood cytopenias (hypersplenism) in patients with nonalcoholic chronic liver disease. Am J Gastroenterol 2000, 95:2936-2939.
3. Laffi G., Cominelli F., Ruggiero M., et al. Altered platelet function in cirrhosis of the liver: impairment of inositol lipid and arachidonic acid metabolism in response to agonists. Hepatology 1988, 8:1620-1626.
4. Peck-Radosavljevic M. Review article: coagulation disorders in chronic liver disease. Aliment Pharmacol Ther 2007, 26(Suppl 1):21-28.
5. Jelkmann W. The role of the liver in the production of thrombopoietin compared with erythropoietin. Eur J Gastroenterol Hepatol 2001, 13:791-801.
6. Tripodi A., Caldwell S.H., Hoffman M., Trotter J.F., Sanyal A.J. Review article: the prothrombin time test as a measure of bleeding risk and prognosis in liver disease. Aliment Pharmacol Ther 2007, 26:141-148.
7. Tessari P. Protein metabolism in liver cirrhosis: from albumin to muscle myofibrils. Curr Opin Clin Nutr Metab Care 2003, 6:79-85.
8. Nagamine T., Ohtuka T., Takehara K., Arai T., Takagi H., Mori M. Thrombocytopenia associated with hepatitis C viral infection. J Hepatol 1996, 24:135-140.
9. García-Suárez J., Burgaleta C., Hernanz N., Albarran F., Tobaruela P., Alvarez-Mon M. HCV-associated thrombocytopenia: clinical characteristics and platelet response after recombinant alpha2b-interferon therapy. Br J Haematol 2000, 110:98-103.
10. Doi T., Homma H., Mezawa S., et al. Mechanisms for increment of platelet associated IgG and platelet surface IgG and their implications in immune thrombocytopenia associated with chronic viral liver disease. Hepatol Res 2002, 24:23.
11. Sanjo A., Satoi J., Ohnishi A., Maruno J., Fukata M., Suzuki N. Role of elevated platelet-associated immunoglobulin G and hypersplenism in thrombocytopenia of chronic liver diseases. J Gastroenterol Hepatol 2003, 18:638-644.
12. Kuter D.J. New drugs for familiar therapeutic targets: thrombopoietin receptor agonists and immune thrombocytopenic purpura. Eur J Haematol Suppl 2008, 69:9-18.
13. Shearer M.J. Vitamin K in parenteral nutrition. Gastroenterology 2009, 137(Suppl):S105-S118.
14. Wada H., Usui M., Sakuragawa N. Hemostatic abnormalities and liver diseases. Semin Thromb Hemost 2008, 34:772-778.
15. Tripodi A., Primignani M., Chantarangkul V., et al. Thrombin generation in patients with cirrhosis: the role of platelets. Hepatology 2006, 44:440-445.
16. Tripodi A., Salerno F., Chantarangkul V., et al. Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology 2005, 41:553-558.
17. Zocco M.A., Di Stasio E., De Cristofaro R., et al. Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development. J Hepatol 2009, 51:682-689.
18. Murata S., Hashimoto I., Nakano Y., Myronovych A., Watanabe M., Ohkohchi N. Single administration of thrombopoietin prevents progression of liver fibrosis and promotes liver regeneration after partial hepatectomy in cirrhotic rats. Ann Surg 2008, 248:821-828.
19. Myronovych A., Murata S., Chiba M., et al. Role of platelets on liver regeneration after 90% hepatectomy in mice. J Hepatol 2008, 49:363-372.
20. Shimabukuro R., Kawanaka H., Tomikawa M., et al. Effect of thrombopoietin on platelet counts and liver regeneration after partial hepatectomy in a rat model. Surg Today 2009, 39:1054-1059.
21. Alkozai E.M., Nijsten M.W., de Jong K.P., et al. Immediate postoperative low platelet count is associated with delayed liver function recovery after partial liver resection. Ann Surg 2010, 251:300-306.
22. Lesurtel M., Graf R., Aleil B., et al. Platelet-derived serotonin mediates liver regeneration. Science 2006, 312:104-107.
23. Balasubramanian S., Paulose C.S. Induction of DNA synthesis in primary cultures of rat hepatocytes by serotonin: possible involvement of serotonin S2 receptor. Hepatology 1998, 27:62-66.
24. Witters P., Freson K., Verslype C., et al. Review article: blood platelet number and function in chronic liver disease and cirrhosis. Aliment Pharmacol Ther 2008, 27:1017-1029.
25. Aytac S., Turkay C., Bavbek N., Kosar A. Hemostasis and global fibrinolytic capacity in chronic liver disease. Blood Coagul Fibrinolysis 2007, 18:623-626.
26. Nagaoka M.R., Kouyoumdjian M., Borges D.R. Hepatic clearance of tissue-type plasminogen activator and plasma kallikrein in experimental liver fibrosis. Liver Int 2003, 23:476-483.
27. Herwald H., Mörgelin M., Dahlbäck B., Björck L. Interactions between surface proteins of Streptococcus pyogenes and coagulation factors modulate clotting of human plasma. J Thromb Haemost 2003, 1:284-291.
28. Poynard T., Marcellin P., Lee S.S., et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998, 352:1426-1432.
29. Davis G.L., Esteban-Mur R., Rustgi V., et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 1998, 339:1493-1499.
30. Trivedi H.S., Trivedi M. Subnormal rise of erythropoietin in patients receiving interferon and ribavirin combination therapy for hepatitis C. J Clin Gastroenterol 2004, 38:595-598.
31. Kaupke C.J., Butler G.C., Vaziri N.D. Effect of recombinant human erythropoietin on platelet production in dialysis patients. J Am Soc Nephrol 1993, 3:1672-1679.
32. Shreiner D.P., Levin J. The effects of hemorrhage, hypoxia, and a preparation of erythropoietin on thrombopoiesis. J Lab Clin Med 1976, 88:930-940.
33. Heathcote E.J., Shiffman M.L., Cooksley W.G., et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000, 343:1673-1680.
34. McHutchison J.G., Manns M., Patel K., et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002, 123:1061-1069.
35. McHutchison J.G., Everson G.T., Gordon S.C., et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009, 360:1827-1838.
36. Hézode C., Forestier N., Dusheiko G., et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009, 360:1839-1850.
37. Mederacke I., Wedemeyer H., Manns M.P. Boceprevir, an NS3 serine protease inhibitor of hepatitis C virus, for the treatment of HCV infection. Curr Opin Invest Drugs 2009, 10:181-189.
38. Bogen S.L., Pan W., Ruan S., et al. Toward the back-up of boceprevir (SCH 503034): discovery of new extended P4-capped ketoamide inhibitors of hepatitis C virus NS3 serine protease with improved potency and pharmacokinetic profiles. J Med Chem 2009, 52:3679-3688.
39. Sharma P., McDonald G.B., Banaji M. The risk of bleeding after percutaneous liver biopsy: relation to platelet count. J Clin Gastroenterol 1982, 4:451-453.
40. Rebulla P. Trigger for platelet transfusion. Vox Sang 2000, 78(Suppl 2):179-182.
41. Mourtzoukou E.G., Pappas G., Peppas G., Falagas M.E. Vaccination of asplenic or hyposplenic adults. Br J Surg 2008, 95:273-280.
42. Kato M., Shimohashi N., Ouchi J., et al. Partial splenic embolization facilitates completion of interferon therapy in patients with chronic HCV infection and hypersplenism. J Gastroenterol 2005, 40:1076-1077.
43. Dienstag J.L., McHutchison J.G. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 2006, 130:231-264.
44. Ghany M.G., Strader D.B., Thomas D.L., Seeff L.B. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009, 49:1335-1374. American Association for the Study of Liver Diseases.
45. Alvarez O.A., Lopera G.A., Patel V., Encarnacion C.E., Palmaz J.C., Lee M. Improvement of thrombocytopenia due to hypersplenism after transjugular intrahepatic portosystemic shunt placement in cirrhotic patients. Am J Gastroenterol 1996, 91:134-137.
46. Colombato L. The role of transjugular intrahepatic portosystemic shunt (TIPS) in the management of portal hypertension. J Clin Gastroenterol 2007, 41(Suppl 3):S344-S351.
47. McHutchison J.G., Dusheiko G., Shiffman M.L., et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med 2007, 357:2227-2236.
48. Accessed December 23, 2009. http://clinicaltrials.gov/ct2/show/NCT00678587.
49. Accessed December 23, 2009. http://www.nplate.com/patient/pdf/nplate_pi.pdf.
50. Accessed December 23, 2009. http://www.promactacares.com/prescribing_information.pdf.
51. Bussel J.B., Cheng G., Saleh M.N., et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007, 357:2237-2247.
52. Wolber E.M., Haase B., Jelkmann W. Thrombopoietin production in human hepatic cell cultures (HepG2) is resistant to IFN-alpha, IFN-beta, and IFN-gamma treatment. J Interferon Cytokine Res 2002, 22:1185-1189.
53. Yamane A., Nakamura T., Suzuki H., et al. Interferon-{alpha}2b-induced thrombocytopenia is caused by inhibition of platelet production but not proliferation and endomitosis in human megakaryocytes. Blood 2008, 112:542-550.
54. Vadhan-Raj S., Cohen V., Bueso-Ramos C. Thrombopoietic growth factors and cytokines. Curr Hematol Rep 2005, 4:137-144.
55. Brown J.R., Demetri G.D. Challenges in the development of platelet growth factors: low expectations for low counts. Curr Hematol Rep 2002, 1:110-118.
56. Smith J.W., Longo D.L., Alvord W.G., et al. The effects of treatment with interleukin-1 alpha on platelet recovery after high-dose carboplatin. N Engl J Med 1993, 328:756-761.
57. Accessed December 23, 2009. http://www.wyeth.com/content/showlabeling.asp?id=500.
58. Artz A.S., Ershler W.B., Rustgi V. Interleukin-11 for thrombocytopenia associated with hepatitis C. J Clin Gastroenterol 2001, 33:425-426.
59. Ghalib R., Levine C., Hassan M., et al. Recombinant human interleukin-11 improves thrombocytopenia in patients with cirrhosis. Hepatology 2003, 37:1165-1171.
60. Lawitz E.J., Hepburn M.J., Casey T.J. A pilot study of interleukin-11 in subjects with chronic hepatitis C and advanced liver disease nonresponsive to antiviral therapy. Am J Gastroenterol 2004, 99:2359-2364.
61. Fontana V., Dudkiewicz P., Jy W., Horstman L., Ahn Y.S. Interleukin-11 for treatment of hepatitis C-associated ITP. Acta Haematol 2008, 119:126-132.
62. Pregnancy - routine anti-D prophylaxis for rhesus negative women (review of TA41) NICE Technology Appraisal Guideline (August 2008), Accessed December 19, 2009. http://www.nice.org.uk/nicemedia/pdf/TA156Guidance.pdf.
63. Ware R.E., Zimmerman S.A. Anti-D: mechanisms of action. Semin Hematol 1998, 35(Suppl 1):14-22.
64. WinRho®SDF prescribing information, Accessed December 19, 2009. http://www.baxter.com/products/biopharmaceuticals/downloads/winrhopi.pdf.
65. Accessed December 19, 2009. http://rhophylac.com/pdf/PI%20Information%20Chart.pdf.
66. de Almeida A.J., Campos-de-Magalhães M., Antonietti C.L., et al. Autoimmune thrombocytopenia related to chronic hepatitis C virus infection. Hematology 2009, 14:49-58.
67. Bussel J.B., Kuter D.J., Pullarkat V., Lyons R.M., Guo M., Nichol J.L. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood 2009, 113:2161-2171.